Answer
Feb 02, 2026 - 01:09 PM
KEYTRUDA (pembrolizumab) is not approved for the general treatment of prostate cancer. However, it may be used in certain cases for patients whose tumors have specific genetic features, such as high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). Always consult your doctor to see if KEYTRUDA is appropriate for your individual situation.
